SCHEMBL20813842

SCHEMBL20813842

COc1ccc2c(I)ncnc2c1-n1ccnc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.42
▸ CYP3A4 P08684 5/20 0.42
▸ CYP2D6 P10635 5/20 0.42
▸ CYP2C19 P33261 5/20 0.42
▸ HSD17B10 Q99714 4/20 0.42
▸ LMNA P02545 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ TDP1 Q9NUW8 3/20 0.40
▸ CGAS Q8N884 1/20 0.39
▸ CYP11B1 P15538 2/20 0.39
▸ CYP11B2 P19099 2/20 0.39
▸ CYP19A1 P11511 2/20 0.39
▸ CD38 P28907 1/20 0.35
▸ PDPK1 O15530 1/20 0.34
▸ CYP2C9 P11712 2/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24067419 0.82 HSD17B10 (0.40) CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10
SCHEMBL20814021 0.77 NOTUM (0.36) CYP19A1PDE1B
SCHEMBL31589030 0.71 CYP19A1 (0.55) CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10
SCHEMBL20813475 0.70 KDM4E (0.41) CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10
Hydrochloric Acid SCHEMBL17583816 0.70 CYP19A1 (0.54) CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10
SCHEMBL24015442 0.69 ENPP1 (0.67) —
SCHEMBL31502050 0.69 ENPP1 (0.67) —
SCHEMBL20813844 0.68 HTR1A (0.49) HPGDPDE5A
SCHEMBL8335624 0.66 CYP19A1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10
SCHEMBL20813845 0.66 NCOA3 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4327882-A2 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER The Board of Trustees of the Leland Stanford Junior University (US) 2024-02-28 — — EP disclosed
WO-2023077083-A1 ENPP1 INHIBITORS AS INHIBITORS OF METASTASIS ANGARUS THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2021226136-A1 ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE ANGARUS THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed
WO-2019051269-A1 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2019-03-14 — — WO disclosed
Send feedback